Kraft Heinz Co vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Kraft Heinz Co trades at $22.3 (market cap $26.66B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.64 (market cap $2.27B). The key difference: Kraft Heinz Co is far larger — about 11.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Kraft Heinz Co pays a 7.12% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| KHC | SLS | |
|---|---|---|
Market Cap | $26.66B | $2.27B |
Volume | 31,300,109 | 4,179,659 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $15.46 |
52-Week Low | $21.21 | $1.39 |
Typical Hold Time | 129 Days | — |
Enterprise Value | $42.98B | $2.14B |
Dividend Yield | 7.12% | — |
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.27, up 1.32% today, with a bearish technical signal but positive earnings beats in recent quarters. The company faces fundamental headwinds, including a net loss of $5.85 billion in 2025 and a negative net income margin of -13.64%, though operating cash flow remains strong at $4.46 billion. Recent news highlights turnaround efforts, such as new product launches and a $700 million reinvestment plan, amid a high dividend yield and mixed analyst sentiment.
The outlook is cautious due to profitability challenges and high debt, but the stock's low valuation (P/E of 13.04, P/B of 0.74) and consistent cash flow offer potential for value investors. Risks include sustained volume declines and competitive pressures, while the consensus price target of $24.50 suggests modest upside if turnaround initiatives gain traction.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →